This patient-centred approach will pioneer immunological, medical, surgical and computational technologies to generate selective therapies that eliminate cancer. The ultimate hope is to achieve long-term, high-quality disease-free survival for cancer patients.
Singula Bio was co-founded by Professors Ahmed Ahmed, the late Enzo Cerundolo and Enda McVeigh from Oxford’s Nuffield Department of Women’s & Reproductive Health. Supported by Oxford University Innovation (OUI), the University’s research commercialisation company, the spin-out has secured generous seed-stage funding from the financial investors, IIU Nominees Ltd.